Ovarian clear cell carcinoma (OCCC) is a rare, aggressive cancer that is difficult to treat with traditional therapies. The study examined 34 patients with treatment-resistant OCCC who received immune checkpoint blockade therapy. Those with PPP2R1A mutations showed median overall survival of over five years, while non-mutated patients had only 9.2 months. Further investigation involving over 9,000 patients indicated that these mutations correlate with improved treatment outcomes across various cancer types, though they are not prognostic markers on their own outside of immune checkpoint inhibitor contexts.
Patients with PPP2R1A-mutant OCCC experienced a median overall survival of more than five years after immunotherapy, significantly outpacing those without the mutation.
While immunotherapy has revolutionized cancer treatment, its effectiveness in ovarian cancer has been limited, yielding low response rates for most patients.
Collection
[
|
...
]